As part of a clinical trial of four drug interventions, a new study found that insulin glargine and liraglutide outperformed the others for type 2 diabetes. All four drug treatments were administered with metformin.
More than 36 U.S. study centers were involved in the research. The results appeared in The New England Journal of Medicine.
“In this trial involving participants with type 2 diabetes of less than 10 years’ duration who were receiving metformin and had glycated hemoglobin levels of 6.8 to 8.5%, we compared the effectiveness of four commonly used glucose-lowering medications,” according to the findings.
“All four medications, when added to metformin, decreased glycated hemoglobin levels. However, glargine and liraglutide were significantly, albeit modestly, more effective in achieving and maintaining target glycated hemoglobin levels.”
Over 5,000 participants, a portion of which are of minority groups, were recruited for the study.
